Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity.
about
Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer CellsThe impact of cellular senescence in cancer therapy: is it true or not?Drugging the addict: non-oncogene addiction as a target for cancer therapyModelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistanceBeneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanomaInduction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF.Therapy-induced senescence in cancerAndrogen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivoDifferential sensitization of different prostate cancer cells to apoptosis.Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma.Mutational status of naevus-associated melanomas.Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.Drug-induced senescence bystander proliferation in prostate cancer cells in vitro and in vivo.Dysfunction of nucleus accumbens-1 activates cellular senescence and inhibits tumor cell proliferation and oncogenesis.Growth factors and oncogenes as targets in melanoma: lost in translation?Gab2-mediated signaling promotes melanoma metastasis.GAB2 induces tumor angiogenesis in NRAS-driven melanoma.Advances in melanoma senescence and potential clinical application.Genetics of melanoma progression: the rise and fall of cell senescence.What makes oncogenes mutually exclusive?Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF.KIT in melanoma: many shades of gray.CpG island hypermethylation frequently silences FILIP1L isoform 2 expression in prostate cancer.How Cancer Genomics Drives Cancer Biology: Does Synthetic Lethality Explain Mutually Exclusive Oncogenic Mutations?
P2860
Q26774625-67182CF3-2899-42B4-83C2-E3714F7932AAQ26825221-ABA999C8-2888-418B-A53F-2862AFC04CC6Q28079559-D73C7206-4956-4CB2-8832-915CAB4F66BCQ28282963-B9FA4C7D-2F33-424B-A19B-36183AFDAE88Q33610782-A089266D-488C-4B0D-A37C-E1EDC8830F75Q33848827-C38BC68E-6DC1-4038-BBB5-F15E18A3BB1CQ34212773-4CFA87C6-3C27-4AEC-A292-031700BBE717Q34295241-406ADBBC-21D6-4E9C-9C4A-D614074AC038Q34370353-1598C00D-B759-43D1-BEB2-D57CDC063152Q35774120-2A39C981-6918-4077-B9FC-A51CEF9CA507Q36095004-4DEF51A3-B420-4FF3-9C99-BA9ECAAA568DQ36176934-EE1A29F5-3C9A-4802-BBA2-9EB4A66C6E92Q36608493-36451CAD-A1E3-46A2-A863-DE194A33B5BDQ36733968-666A6F3B-DF9E-420F-BF49-DF77B431DC5AQ37045217-38EED71A-8307-4697-9739-97B7444A0405Q37164581-44ECF782-E494-4305-8C0C-547F87BB5ACAQ37270065-B219138E-88C6-46F0-9F72-211C920910A9Q37818577-734F39A8-6AB0-4920-916B-E9CBFFFB8BEBQ38589518-47626BC7-F1D5-4D2B-9074-5C63BBA5F7EEQ39602248-16AD6CE2-B0D4-4C90-A1BF-AE3E21E0260CQ40885761-AFD85326-03C9-45B7-BD21-B07EA04F53B4Q41602732-854C6C2E-30F1-41ED-A0AA-712EB8D8EA02Q43240843-70BFD108-4C81-47B0-ACDB-52C456C78B59Q53547702-A29331F9-207C-448F-B43D-F0A531B5A62F
P2860
Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Coexpression of NRASQ61R and B ...... to cell-mediated cytotoxicity.
@en
type
label
Coexpression of NRASQ61R and B ...... to cell-mediated cytotoxicity.
@en
prefLabel
Coexpression of NRASQ61R and B ...... to cell-mediated cytotoxicity.
@en
P2093
P1433
P1476
Coexpression of NRASQ61R and B ...... to cell-mediated cytotoxicity
@en
P2093
Alessandra Molla
Carlotta Petti
Claudia Vegetti
Soldano Ferrone
P304
P356
10.1158/0008-5472.CAN-05-4671
P407
P577
2006-07-01T00:00:00Z